HALOZYME THERAPEUTICS plans to offer $1.05 billion of convertible senior notes due 2033, with an option for up to $150 million more. Proceeds are intended for capped calls, repurchases of existing notes and general corporate purposes, while the capped calls are generally expected to reduce potential common-stock dilution.

Key Highlights

  • Halozyme may allow initial purchasers to acquire up to an additional $150 million of the convertible notes.
  • The notes will be senior, unsecured obligations with interest paid semi-annually in arrears.
  • Proceeds may support repurchases of 0.25% notes due 2027 and 1.00% notes due 2028.

HALOZYME THERAPEUTICS, INC. (NASDAQ: HALO) plans to offer $1.05 billion of convertible senior notes. The proposed financing would give the company proceeds for capped call transactions, existing-note repurchases and broader corporate purposes, subject to market conditions and other factors.

$150 Million Additional Note Option Initial

purchasers may acquire up to an additional $150 million of the convertible notes. The securities are intended for qualified institutional buyers under Rule 144A and will rank as senior, unsecured obligations of Halozyme. Interest will be paid semi-annually in arrears, with Maturity set for October 1, 2033, unless the notes are redeemed, repurchased or converted earlier. Conversion will be limited by specified conditions before April 1, 2033. From that date until shortly before maturity, holders may convert regardless of those conditions, while Halozyme may settle conversions in cash and, if applicable, common stock.

Capped Calls and Existing Note Repurchases

Halozyme expects to use part of the net proceeds to fund privately negotiated capped call transactions. The company also expects to repurchase certain outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028 for cash. Remaining proceeds may fund working capital, capital expenditures, potential acquisitions, strategic transactions and future note repurchases, including repayment at maturity or earlier optional redemption. The capped calls are generally expected to reduce potential dilution or offset certain cash payments above principal, although dilution or the absence of an offset could remain if the common-stock price exceeds the capped-call price.